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Background: Resident memory T cells have emerged as key players in the immune 
response generated against a number of pathogens. Their ability to take residence in 
non-lymphoid peripheral tissues allows for the rapid deployment of secondary effector 
responses at the site of pathogen entry. This ability to provide enhanced regional immu-
nity has gathered much attention, with the generation of resident memory T cells being 
the goal of many novel vaccines.
Objectives: This review aimed to systematically analyze published literature investiga-
ting the role of resident memory T cells in human infectious diseases. Known effector 
responses mounted by these cells are summarized and key strategies that are potentially 
influential in the rational design of resident memory T cell inducing vaccines have also 
been highlighted.
methods: A Boolean search was applied to Medline, SCOPUS, and Web of Science. 
Studies that investigated the effector response generated by resident memory T cells 
and/or evaluated strategies for inducing these cells were included irrespective of pub-
lished date. Studies must have utilized an established technique for identifying resident 
memory T cells such as T cell phenotyping.
Results: While over 600 publications were revealed by the search, 147 articles were 
eligible for inclusion. The reference lists of included articles were also screened for other 
eligible publications. This resulted in the inclusion of publications that studied resident 
memory T cells in the context of over 25 human pathogens. The vast majority of studies 
were conducted in mouse models and demonstrated that resident memory T  cells 
mount protective immune responses.
conclusion: Although the role resident memory T cells play in providing immunity varies 
depending on the pathogen and anatomical location they resided in, the evidence overall 
suggests that these cells are vital for the timely and optimal protection against a number 
of infectious diseases. The induction of resident memory T cells should be further inves-
tigated and seriously considered when designing new vaccines.
Keywords: resident memory t cells, infectious diseases, vaccine development, immunity, microbiology
FiguRe 1 | Literature search strategy. The search strategy used revealed 381 records in Medline (Ovid), 416 in SCOPUS, and 517 in Web of Science. This resulted 
in a total number of 1,314 records. After removing duplicates, there were 604 records. Screening of titles resulted in the exclusion of 257 records, as they did not 
address resident memory T cells, human infectious diseases, or neither. Others records were excluded as they were reviews, editorials, meeting abstracts, book 
chapters, poster presentations, or erratum notifications. The abstracts of the remaining 347 records were analyzed and a further 124 publications were excluded 
due to their focus on TRM biology. The full texts of the remaining studies were reviewed. 81 of these texts were excluded for aforementioned reasons. Co-authors 
were consulted when there was ambiguity regarding the relevance of a study. In total, 142 publications from the search were included. 5 additional studies were 
included by screening the references of studies from the search results and following external review.
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iNtRODuctiON
Traditionally, memory T cells have been subdivided into two 
broad categories: effector memory and central memory T cells 
(TEM and TCM, respectively). After the realization that some 
memory T  cells fail to egress out of peripheral tissues back 
into the blood stream, it became clear that this dichotomous 
distinction of memory T cells did not account for the complete 
diversity of the memory T  cell population. This led to the 
discovery of a third subset of memory T  cell. Appropriately, 
dubbed “Tissue-resident memory T cells” (here after referred 
to as TRM), this newly defined population exhibits the unique 
feature of remaining localized in peripheral tissues (1). As 
such, these cells provide enhanced localized immunosurveil-
lance and protection of peripheral tissues when compared to 
TEM and TCM. TRM have been characterized in many peripheral 
tissues, including skin, lungs, brain, liver, the female reproduc-
tive tract, and the gastrointestinal mucosa. Given the huge 
variance in their location of residence, this subset of memory 
cell is highly heterogeneous, phenotypically varying depend-
ing on their anatomic location and the inflammatory cues 
produced by their respective microenvironment. Although 
experimental techniques such as parabiosis can definitively 
distinguish TRM from circulating memory T  cells, other less 
complex methods of identifying TRM are more frequently used. 
The co-expression of CD69 and CD103 is commonly used as 
a marker of tissue residence, although it appears not all bona 
fide TRM are defined by this particular phenotype. Regardless, 
TRM have been implicated in a wide range of physiological 
functions, such as providing protection against pathogens and 
cancerous cells, as well as in many pathological states such as 
autoimmune and other inflammatory diseases. The exploration 
of TRM biology and the role they play in maintaining homeo-
stasis has broad implications for human health. Currently, our 
understanding of TRM function is largely constrained within 
the context of infectious diseases. As of now, it appears that 
TRM are better adapted to providing rapid protection against 
pathogen invasion when compared to their circulating counter 
parts (2–4). Thus, vaccines of the future would ideally establish 
a population of protective TRM at the portals of entry most at 
risk of pathogen invasion to provide immediate and effective 
immunity, rather than relying on the delayed recruitment of 
effector cells from the circulating pool of memory cells. Since 
parenterally administered vaccines induce minimal tissue-
specific protection, current routes of administering vaccines 
may need to be revised (5, 6). The present review will primarily 
focus on the role of TRM in the immune response generated to 
a range of human pathogens and discuss future avenues for the 
development of TRM-based vaccines.
metHODOLOgy
A systematic search of published literature was conducted. 
Literature was critically evaluated for evidence of the role TRM 
play during infections and in vaccinology. A flowchart sum-
marizing our methodology has been included (Figure 1). The 
preparation of this review was guided by the PRISMA-P 2015 
guideline (7).
FiguRe 2 | Illustration of human-relevant diseases for which a role of TRM has been reported. TRM have been studied in 16 viral diseases (top left), seven bacterial 
diseases (top right), five parasitic diseases (bottom left), and one fungal disease (bottom right). Pathogens have been grouped according to organs or organ systems 
that have been studied in the context of TRM, including the respiratory, gastrointestinal, and urogenital tracts, as well as brain, skin, liver, lymphatics, and circulation. 
Nippostrongylus brasiliensis and Heligmosomoides polygyrus are mouse pathogens for human Necator americanus and gastrointestinal helminth infections, 
respectively. Image modified from https://commons.wikimedia.org/wiki/File:Female_shadow_anatomy_without_labels.svg.
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Final searches of literature were performed on March 23, 2018 
in Medline, SCOPUS and Web of Science by the first author. The 
Boolean search strategy used was as following (“resident memory 
t cell*” OR “t resident memory cell*” OR “tissue resident memory 
cell*” OR “resident memory” OR “tissue memory”). The refer-
ences of included studies were also screened for other relevant 
publications.
Both human and animal studies that use surface markers of 
residence or other established techniques such as intravascular 
staining and parabiosis to illustrate localization of T  cells to 
peripheral tissues, as well as T cell phenotyping were included. 
Studies were also screened for their relevance to human patho-
gens, and thus animal infection models that are analogous to 
human infectious diseases were included. Studies were included 
irrespective of published date. Only published and accepted 
manuscripts of original research were included. Publications 
that primarily focused on TRM biology (ontogeny, cellular 
metabolism, etc.) or non-infectious diseases were not included. 
Certain non-communicable diseases such as hepatocellular 
carcinoma and cervical cancer that can be caused by pathogens 
are briefly mentioned within the broader discussion of TRM-
mediated immunity.
ReSuLtS OF SeaRcH
The results of the search strategy are summarized in Figure 1.
Data SyNtHeSiS aND aNaLySiS
The first author conducted extraction of data from relevant 
studies. This review has been divided into sections based on 
pathogen type: viruses, bacteria, parasites/helminths, and fungi 
(Figure 2). The studies included in this review contain the most 
relevant findings related to immune responses generated by TRM 
against human pathogens, or make use of novel strategies for TRM 
generation. We apologize to authors whose work could not be 
included in this review.
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tHe ROLe OF tRm iN viRaL iNFectiONS
As of present, TRM immune responses are by far mostly studied in 
the context of viral pathogens. The following section will present 
findings by specific viral pathogen/viral disease.
HeRPeS SimPLeX viRuS (HSv)
Herpes simplex virus causes infections that present with a 
varying range of symptoms. The primary clinical manifesta-
tions of HSV infection are intraepithelial vesicles. There are 
two antigenically distinct HSV subtypes: HSV-1 and HSV-2, 
causing cold sores and genital warts, respectively (8). However, 
both sub-types can be the etiology of either clinical disease 
as sexual transmission allows for spread between the two sites 
(9). Both viruses establish a life-long latent infection within 
the surrounding nervous tissue, and control of HSV infection 
requires effective cell-mediated immune responses to prevent 
reactivation. However, co-morbid illnesses, immunosuppres-
sive drugs, UV exposure, and psychological stress can hinder 
immune control. A number of studies suggest that TRM are 
implicated in controlling HSV-1 latency in the trigeminal gan-
glia (10). HSV-1 infection models primarily focus on infections 
of the skin and nervous tissue such as the trigeminal ganglia 
and the eyes (11–22). Following acute infection with HSV-1, 
CD8+ TRM remain localized to the skin initially infected and 
are also found surrounding latently infected sensory ganglia 
(11). However, evidence suggests that multiple exposures to 
cognate antigen can substantially increase the TRM population 
in not only the site of HSV infection, but also in distant skin 
(12). CD8+ skin TRM appear to resemble the antigen-presenting 
Langerhans cells of the skin, extending dendritic projections 
into the surrounding tissue, probably in an attempt to survey 
the local area for antigen (13). This is supported by evidence 
from confocal microscopy and intravital imaging (21) that 
suggests these TRM can travel between keratinocytes (13). 
However, unlike Langerhans cells, these TRM do not extend 
into the stratum corneum (13, 17). It also appears that skin 
TRM are not specifically attracted to virally infected cells, and 
thus migrate throughout the epidermis in a random manner 
(17, 21). By extension, it can be inferred that skin TRM may 
take a considerable period of time before identifying virally 
affected cells. As such, it may be safe to assume that a critical 
mass of skin TRM is needed in order to afford timely protection. 
This notion is supported by the observation that protection 
appears to be dependent upon the local density of TRM (17). 
Upon antigen recognition, skin TRM undergo a change in their 
morphological and motility pattern, decelerating their migra-
tory rate and losing their dendricity (13, 17). This is probably 
indicative of a shift in role from immunosurveillance to effector 
function. Furthermore, the maintenance of HSV-1-specific TRM 
populations appears to be independent of circulating T  cells 
in both skin and trigeminal ganglia (14, 17). Skin TRM appear 
to be able to sustain their numbers through local proliferation 
after secondary infection (17). However, after a combined 
corticosterone and stress-induced reduction of trigeminal 
ganglia CD8+ T cells (presumably TRM), there appeared to be 
no increased proliferation of remaining T cells when compared 
to the homeostatic proliferation rates as indicated by BrdU 
incorporation (14). Analysis of HSV-1-specific skin and dorsal 
root ganglia TRM during acute immunity and later time points 
revealed that transcription of cytolytic molecules decreases 
with time. As such, TRM-based immunity in the long term may 
not be reliant on enhanced cytolytic effector functions, but 
rather on the localization of these cells at sites susceptible to 
reinfection (15). The chronic inflammatory response induced 
by persistent viral gene expression during latency leads to TRM 
exhaustion in the brain ependymal region, rendering them 
unable to control HSV-1 infection (16). Perhaps the reason why 
TRM downregulate their cytolytic genes during times of homeo-
stasis is because continuous expression may lead to exhaustion. 
Nevertheless, it appears that the generation of CD8+ TRM in 
skin and ganglia may be a viable option for protection against 
HSV-1 infection or reactivation. Local inflammation of the 
skin and mucosa alone can encourage the recruitment of TEM 
to these peripheral sites where differentiation into the TRM 
phenotype occurs. This was demonstrated using 2,4-dinitro-
fluorobenzene, a contact-sensitizing agent. Furthermore, the 
application of nonoxynol-9 (a spermicide agent) to the female 
genital tract enhanced protection against HSV challenge, 
correlating with higher numbers of CD103+ T cells localizing 
to the epithelium (19). Hence, agents that can be applied to 
specific tissue and that cause a localized, general inflammatory 
response may be a strategy worth exploring for the genera-
tion of TRM. More specifically, however, the CXCL10/CXCR3 
chemokine pathway appears to be vital in generating TRM, as 
mice deficient in either CXCL10 or CXCR3 were unprotected 
against HSV-1 UV-B light-induced reactivation challenge. 
Furthermore, the administration of CXCL10 into deficient mice 
through the use of a neurotropic virus vector amplified TRM in 
the trigeminal ganglia, conferring better protections against 
reactivation challenge (20). CXCL10 administration through 
the use of a rAAV8-CamKIIa-GFP-CamKIIa-CXCL10 vector 
showed similar results (18). Samples from human patients that 
were asymptomatic but seropositive for HSV-1 infection were 
used to determine which 467 HLA-A*0201-restircted CD8+ 
T cell epitopes were immunodominant in the HSV-1-specific 
immune response. These asymptomatic individuals generated 
a high number of polyfunctional CD8+ TEM against three 
epitopes. HLA-A*0201 transgenic mice were primed with these 
epitopes and subsequently treated with an ocular topical prepa-
ration containing rAAV8-CamKIIa-GFP-CamKIIa-CXCL10 
to deliver exogenous CXCL10 chemokine. Results from UV-B 
reactivation challenge demonstrated that this strategy was 
able to reduce viral shedding in tears and recurrent herpetic 
ocular disease (18). This strategy may be beneficial in rationally 
developing novel vaccines against other diseases.
Human studies have also been conducted in HSV-2 infection. 
Samples from the genital tract of HSV-2-infected women con-
tained populations of HSV-2-specific T cells with a TRM phenotype 
(23). More interestingly, a population of CD8αα+ TRM that reside 
at the dermal–epidermal junction have also been described in 
biopsies of HSV-2-infected humans. This unique positioning sug-
gests that these cells may be able to survey the neural tissue from 
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which virus travels to the skin during reactivation (24). Thus, TRM 
play a role in the natural immune response against HSV-2 infec-
tion. Although it was already demonstrated that T  cells could 
be recruited to peripheral tissues using inflammatory agents 
(19), the “prime and pull” vaccine strategy was first described 
in a HSV-2 infection model (25). In this study, the investigators 
explored the novel idea of parenterally immunizing mice and 
subsequently topically administering CXCL10 into the vagina 
before challenging with HSV-2. Mice that underwent the prime 
and pull protocol showed minimal signs of clinical disease and 
had a survival rate of 100%. Naive and parenterally immunized 
mice that did not receive the pull treatment developed clinical 
disease and exhibited high mortality rates. This strategy also dem-
onstrated the capacity to prevent infection of sensory neurons 
(25). Further investigation of this protocol revealed that immu-
nity was largely dependent on INF-γ produced by CD8+ TRM (26). 
Re-stimulation of this CD8+ TRM was dependent on a population 
of CD301b+ dendritic cells that resided in the lamina propria. 
In fact, depletion of CD301b+ dendritic cells using a diphtheria 
toxin model rendered the prime and pull strategy ineffective and 
mice suffered high morbidity and mortality rates (26). Although a 
non-specific inflammatory stimulus such as nonoxynol-9 may be 
sufficient to pull CD8+ T cells in to the female reproductive tract 
and subsequently convert them to TRM, it appears that antigen 
presentation by CD301b+ dendritic cells is needed for CD8+ TRM-
mediated immunity at this site. A different study that made use 
of a topical vaccine containing a human papillomavirus (HPV) 
vector expressing gB and gD ectodomains of HSV-2 has shown 
the capacity to generate TRM in the reproductive tract, and reduce 
viral shedding and clinical disease (27). This study highlights the 
capacity of HPV vectors to induce TRM in the genital tract, a vac-
cine strategy that may be applicable to other sexually transmitted 
infections. HSV-2-specific CD8+ TRM can also be generated using 
a “chemical-free and biological-free” laser adjuvant, a protocol 
that could be explored in other infectious models (28). While the 
vast majority of studies have assessed the protective capabilities of 
CD8+ TRM during HSV infection, very few studies have analyzed 
the role of CD4+ TRM in HSV infections (21, 29). Intravaginal 
vaccination of mice with thymidine kinase negative HSV-2 (an 
attenuated form of the virus) provided full protection against 
challenge with wild-type HSV-2, independent of CD8+ T  cells 
and B cells. Instead, parabiosis studies demonstrated that CD4+ 
TRM are required within the genital tract mucosa for immunity in 
this model. These CD4+ TRM are polyfunctional, secreting IFN-γ, 
TNF-α, and IL-2, and resided in organized, non-tertiary immune 
structures called memory lymphocyte clusters (MLCs). These 
MLCs appear to assemble under the influence of macrophage-
secreted CCL5. Upon antigen stimulation, the CD4+ TRM within 
the MLCs expand and secrete high levels of IFN-γ. The investiga-
tors of this study also report that circulating memory T cells were 
“barely recruited” when MLCs were present in the mucosa. This 
suggests that CD4+ TRM may be capable of clearing or control-
ling infection even before recruiting signals are generated in a 
magnitude large enough to attract circulating T cells to the site of 
infection (29). It still remains necessary to explore whether a criti-
cal mass of CD4+ TRM-containing MLCs are needed within the 
genital tract to provide protection. It is likely that this profound 
role of CD4+ TRM in mediating immunity during HSV-2 infection 
is due to the location of the infection (genital tract) rather than 
the viral factors alone. This is supported by the fact that MLCs 
have also been found in the genital tract of both human and mice 
secondary to infections caused by a bacterial pathogen [refer to 
Chlamydia trachomatis (Ct) section of this review]. Despite the 
difficulties in generating CD4+ TRM following prime and pull 
vaccination, an ideal vaccine against HSV-2 should generate 
CD8+ and CD4+ TRM (25).
iNFLueNZa
Influenza viruses are a major cause of respiratory infections. 
Although influenza vaccines have been in use for many years, 
antigenic drift of surface hemagglutinin and neuraminidase 
proteins require annual immunizations. Antigenic shift can 
result in highly virulent strains of influenza that cause devastat-
ing pandemics (30). The ideal influenza vaccine would provide 
heterotypic immunity that prevents the escape of newly mutated 
viruses. Current influenza vaccines rely on generating high neu-
tralizing antibody titers to protect against infection. Although 
this strategy has demonstrated efficacy in mediating protection, 
the inability of antibodies to neutralize new variants of the virus 
has sparked research into alternate strategies (31). Growing 
evidence suggests that efforts should be focused on developing 
vaccines that generate TRM-mediated immunity (32). Analysis of 
human samples has revealed that influenza-specific TRM can be 
found in substantial numbers in lung tissue, highlighting their 
role in natural infection (33, 34). Despite expressing low levels 
of granzyme B and CD107a, these CD8+ TRM had a diverse T cell 
receptor (TCR) repertoire, high proliferative capacities, and 
were polyfunctional (34). Influenza infection history suggests 
a greater level of protection against re-infections likely due to 
the accumulation of CD8+ TRM in the lungs (35). Furthermore, 
the natural immune response to influenza A virus infection 
in a rhesus monkey model demonstrated that a large portion 
of influenza-specific CD8+ T cells generated in the lungs were 
phenotypically confirmed as CD69+CD103+ TRM (36). Unlike 
lung parenchymal TRM, airway CD8+ TRM are poorly cytolytic and 
participate in early viral replication control by producing a rapid 
and robust IFN-γ response (37, 38). Bystander CD8+ TRM may 
also take part in the early immune response to infection through 
antigen non-specific, NKG2D-mediated immunity (39). The 
generation of functional TRM that protect against heterosubtypic 
influenza infection appear to be dependent on signals from CD4+ 
T cells (40). A role for CD4+ TRM has also been reported (41). 
Much like their CD8+ counterparts, CD4+ TRM also produce a 
significant IFN-γ response during early infection (42, 43). Aside 
from the CD8+ and CD4+ subsets of TRM, a subset of NK1.1+ dou-
ble negative T memory cells which reside in the lungs also play a 
role in influenza infection (44). Taken together, these studies and 
others (45–47) demonstrate that TRM are required for optimal 
protection. However, unlike TRM in other locations, such as the 
skin, lung TRM are not maintained for extended periods of time. 
This gradual loss of lung TRM appears to be the reason for the loss 
in heterotypic immunity against influenza infection (45, 46, 48). 
Lung TRM exhibit a transcriptional profile that renders them 
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susceptible to apoptosis (48). Despite conflicting evidence (49), 
it appears that maintenance of the lung CD8+ TRM populations 
relies on the continual seeding from circulating CD8+ T  cells. 
However, with time, circulating CD8+ T cells adopt a transcrip-
tional profile that reduces their capacity to differentiate into 
TRM. Expanding the CD8+ TEM compartment through booster 
vaccination may circumvent the problem of these time-sensitive 
transcriptional changes (48). There is also conflicting evidence 
regarding the requirement of local antigen for the generation 
of TRM within the lung (48, 50). Continuing to find ways to 
generate and maintain lung TRM is of great importance for vac-
cines against pulmonary infections. Intranasal administration 
of vaccines seems to encourage the development of a strong 
mucosal immune response (51, 52). Intranasal administration 
of Live Attenuated Influenza Vaccine (FluMist) in a mouse 
model induced both CD4+ and CD8+ TRM that provided a degree 
of cross-strain protection independent of TCM and antibodies 
(53). The intranasal administration of a PamCys2 or Adjuplex 
has demonstrated capacity for producing protective influenza-
specific lung CD8+ TRM in similar numbers and IFN-γ secreting 
potential when compared to the natural response to influenza 
infection (54, 55). Furthermore, a vaccine containing virus-like 
particles with tandem repeat M2e epitopes generated heterotypic 
immunity through the induction of antibodies, and protection 
correlated with IFN-γ-secreting CD8+ TRM (56). A Modified 
Vaccinia Ankara-vectored virus expressing conserved influenza 
nucleoprotein and matrix protein 1 elicited an IFN-γ secreting 
CD4+ T cell and CD8+ TRM response (57). Co-administration of 
4-1BBL (CD137 signal) along with an influenza nucleoprotein 
expressing replication defective adenovirus vector via the intra-
nasal route stimulated and boosted a lung CD8+ TRM response 
through the recruitment of circulating T  cells (58). Intranasal 
administration of 4-1BBL may serve as a promising “pull” 
strategy in systemically primed individuals. Another potential 
“pull” strategy is the intranasal administration of Fc-fused IL-7. 
This protocol was used as a pre-treatment before influenza A 
infection, and demonstrated protective capacities in mice against 
lethal challenge. It appears that Fc-fused IL-7 recruits polyclonal 
circulating T cells into the lungs, which subsequently reside in 
the lung tissue as “TRM-like cells” (59). Intranasal administration 
of Fc-fused IL-7 after systemic priming may be able to recruit 
influenza-specific T cells into the lungs, and may be a strategy 
for inducing lung TRM. An antibody targeted vaccination strategy 
in which antigens are coupled to monoclonal antibodies against 
CD103+ or DNGR-1+ dendritic cells has also been shown to elicit 
a protective CD8+ TRM response (47, 60).
HumaN immuNODeFicieNcy  
viRuS (Hiv)
Human immunodeficiency virus is a retrovirus that is trans-
mitted via contact with infected blood and other fluids such 
as semen and vaginal secretions. The virus specifically targets 
the surface proteins CD4, CXCR4, and CCR5, with the natu-
ral progression of disease resulting in the depletion of CD4+ 
T  cells. As a consequence, infected individuals are left in an 
immunocompromised state referred to as aquired immuno-
deficieny syndrome (AIDS), which is characterized by fatal 
opportunistic infections and malignancies. Although the 
development of therapeutics such as anti-retroviral therapy has 
reduced the incidence of AIDS, HIV/AIDS continues to con-
tribute significantly to global morbidity and mortality. Evidence 
shows that CD8+ T cells are vital in controlling early infection 
(61). Studies of human tissue samples have revealed that TRM 
are generated in response to HIV infection in multiple locations 
including the gastrointestinal tract and the female reproductive 
tract (62–65). Furthermore, individuals who appeared to natu-
rally control infection had TRM that were capable of producing 
the highest polyfunctional immune responses when compared 
to individuals who did not. However, the TRM population within 
the HIV-specific CD8+ T cell compartment in individuals who 
controlled infection was under-represented when compared to 
individuals who were viremic (62). Although not confirmed, 
this may be due to the higher ability of polyfunctional TRM in 
these individuals to recruit circulating T  cells, thereby only 
altering the TRM proportion. Similar to other infections in vari-
ous sites, CD8+ TRM in the context of HIV can be sub-divided 
into two subsets based on the expression of CD103 (62, 63). 
Analysis of the ectocervial epithelium and menstrual blood 
revealed that HIV-infected women were more likely to have 
CD103− TRM when compared to healthy individuals (63, 64). 
This reduced expression of CD103 may be explained by the 
HIV-induced depletion of CD4+ T  cells which appear to be 
vital in providing help to CD8+ T cells for up-regulating CD103 
(64). The CD103− populations of the ectocervix resided closer 
to the basement membrane of the epithelium when compared to 
their CD103+ counterparts. Interestingly, the CD103+ popula-
tion from infected individuals appears to express higher levels 
of PD-1 (63). In a separate study, adipose PD-1+ CD4+ TRM, 
appeared to remain relatively inactive during HIV infection 
and may serve as a reservoir for HIV (65). As such chronically 
activated TRM and TRM exposed to immunomodulated environ-
ments (such as the adipose tissue) may be unable to elicit a full 
effector response, favoring the progression of HIV infection. 
It also appears that HIV has the ability to disrupt CCR5-
mediated CD8+ T  cell migration into the cervical mucosa, 
thereby impairing the development of TRM populations (66). 
Regardless, human studies suggest that TRM, especially CD8+ 
TRM, play an important role in combating HIV infection and 
thus may be valuable targets for vaccine development. Since the 
most common mode of transmission of HIV is through sexual 
intercourse, it may be desirable to explore strategies that induce 
anti-HIV CD8+ TRM in the female and male reproductive tract 
and rectosigmoid epithelium. In a Simian Immunodeficiency 
Virus model of rhesus macaques, intravenous administration 
of SIVmac239Δnef generated a population of CD8+ TRM in the 
vaginal tissue and the gut that participated in protection (67). 
In a murine model, a mucosal vaccination strategy in which 
intranasal administration of an influenza-vector expressing 
the HIV-1 Gag protein p24 followed by an intravaginal booster 
induced CD8+ TRM in the vagina. Antigen stimulation of these 
CD8+ TRM resulted in the recruitment of B cells, natural killer 
cells, and CD4+ T  cells (68). While the recruitment of innate 
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and adaptive immune cells may be beneficial in early viral 
clearance, the recruitment of CD4+ T cells may be detrimental 
in the context of HIV as they are the target for HIV. Hence, 
incidental recruitment of CD4+ T  cells to sites of HIV entry 
(female reproductive tract and rectum) by prime and pull vac-
cination strategies may unintentionally increase susceptibility 
to infection. A micro-needle array delivery system that utilizes 
a recombinant adenovirus vector containing the HIV-1 protein 
Gag, has also produced promising results in generating TRM. 
These HIV-specific TRM were found in the female reproductive 
tract and respiratory tract of immunized mice and responded to 
local antigenic stimulation through expansion and production 
of IFN-γ and granzyme B (69). Using this micro-needle array 
delivery system as a priming strategy followed by intravaginal 
delivery of a booster concoction serving as a pull strategy may 
be an interesting protocol worth exploring.
vacciNia
Vaccinia is a poxvirus that usually causes a very mild or asymp-
tomatic infection in immunocompetent individuals. Immunity 
to vaccinia virus also provides sufficient protection against small-
pox, which allowed for its eradication following administration 
of the live vaccinia virus (70). Despite elimination, smallpox 
remains a priority on the global agenda given the potential for the 
virus to be used as a biological weapon (71). For this reason and 
its ability to serve as a vector, vaccinia virus continues to be used 
in research. Murine models demonstrate that TRM are generated 
in response to vaccinia and play a significant role in mediating 
protection against infection (72–76). Dermal-resident γδ T cells 
have also been implicated in the immune response against cuta-
neous vaccinia infection (77). Following skin infection CD8+ 
T cells are recruited independently of CD4 T+ cells and IFN-γ 
(72), many of which subsequently assume the TRM phenotype 
(72, 73, 75, 78, 79) and are capable of initiating potent inflamma-
tory responses upon re-stimulation (79). Of particular interest 
is the capacity of local vaccinia skin inoculation to globally seed 
skin tissue even at remote sites with long lasting TRM (72) as 
well as generating TRM responses in non-related non-lymphoid 
organs such as the lungs and liver (76). Multiple exposures to 
cognate viral antigens have also shown to selectively expand TRM 
(72, 73, 78, 79). In a lung infection model of vaccinia, higher 
numbers of lung TRM correlated with better protection against 
subsequent infection as indicated by a rapid reduction in viral 
loads. TRM seem to expand more rapidly and localize to the 
infection site as indicated by a 5-ethynyl-2′-deoxyuridine prolif-
eration assay when compared to their circulating counter parts. 
Depletion of lung CD8+ T cells by intranasal administration of 
αCD8 antibody, resulted in previously protected mice becoming 
susceptible to infection, indicating that CD8+ TRM play a vital 
role in mediating immunity (74). In another study, parabiosis 
experiments demonstrated that TRM were exceedingly better at 
clearing vaccinia virus skin infection than TCM within a shorter 
timeframe. In fact, it appears that skin TRM can clear vaccinia 
skin infection even in the absence of neutralizing antibodies 
and TCM (72). However, vaccinia-specific CD8+ skin TRM appear 
to have an impaired ability to recruit circulating effector cells 
during polymicrobial sepsis infection (80). Whether there are 
other physiologically challenging conditions that impair skin 
TRM functionality remains largely unexplored. Surprisingly, 
vaccinia lung infection revealed that not all TRM are equally 
capable of conferring protection. TRM that resided in the lung 
interstitium were better positioned to rapidly kill infected lung 
cells in a contact-dependent manner when compared to TRM 
situated in association with the tissue vasculature. Furthermore, 
TRM found within the interstitium, unlike vascular-associated 
TRM, were able to up-regulate CD69 expression, potentially indi-
cating an enhanced ability to respond during early infection (74). 
Investigations of vaccinia infection has also reinforced that 
epithelial immunization routes, such as skin scarification and 
intranasal exposure, demonstrate significant efficacy for gener-
ating protective TRM responses (72–76, 78). In fact, vaccination 
via skin scarification is capable of protecting against clinical 
disease (pock lesions of the skin) whereas not all mice vacci-
nated via systemic routes such as intramuscular and intraperi-
toneal were protected from pock lesions. More astonishingly, 
mice immunized via skin scarification demonstrated greater 
resistance to disease when challenged via a heterologous route 
(intranasal), compared to mice immunized subcutaneously or 
intraperitoneally, in spite of generating reduced antibody titers 
(75). These observations may be attributed to TRM-mediated 
immunity given the evidence that TRM can be generated in 
distant tissues after skin scarification (76). Overall, studies that 
use vaccinia infection models have shed light on the ability 
of skin scarification to elicit a robust and somewhat unique 
immune response.
ReSPiRatORy SyNcytiaL viRuS (RSv)
Respiratory syncytial virus is a common cause of lower res-
piratory tract infections in children and the elderly. Common 
reinfection with RSV suggests absence of protective immunity 
(81). A number of studies have shown the importance of TRM 
in providing protection against RSV (82–86). An experimental 
human infection study showed that adults with higher frequen-
cies of RSV-specific CD8+ T  cells, many of which displayed a 
TRM phenotype, developed less severe lower respiratory tract 
symptoms and reduced viral loads. This increase in protection 
was not correlated with higher numbers of circulating CD8+ 
T cells, suggesting the localization of TRM was vital for mediat-
ing immediate protection (82). TRM induction in lung tissue and 
airway fluid was also demonstrated following intranasal RSV 
infection in mice. Adoptive transfer of airway lymphocytes from 
RSV-infected mice into naïve recipients reduced disease burden 
upon infection challenge, compared to adoptive transfer of 
airway lymphocytes from sham-infected mice. It was concluded 
that both airway CD8+ and CD4+ T cells play a role in protecting 
against RSV infection and reducing disease severity, respectively 
(83). However, given that only bulk CD4+ or CD8+ T cells were 
transferred, it remains to be investigated if the protective capacity 
is mediated by airway TEM or TRM cells. In support of the latter, an 
African green monkey model of RSV infection illustrated that 
antibody and CD4+ T cell responses are unlikely to protect against 
reinfection. On the contrary, it appears that lung CD8+ T cells, of 
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which up to half displayed a TRM phenotype, were more capable 
of protecting against secondary infection (84). From the available 
evidence (82–86), it appears that an ideal RSV vaccine should 
elicit a CD8+ TRM response in the lung. Of note, some experi-
mental RSV vaccines have already shown promising results with 
regards to TRM generation: intranasal administration of an RSV 
antigen-expressing murine cytomegalovirus generated an IFNγ- 
and MIP-1β-secreting population of TRM (85); co-administration 
of the TLR9 agonist CpG and an inhibitor of notch signaling 
(L-685,458) with formalin-inactivated RSV elicited a strong pro-
tective TRM response (86); intranasal administration of virus-like 
particles containing RSV M and M2 proteins as antigen delivery 
systems has also shown propensity to induce the production 
of TRM (87); and a dendritic cell-Listeria monocytogenes immu-
nization strategy, when administered locally, was able to avoid 
circulating T cell-induced immunopathology and protect against 
RSV infection challenge through the generation of TRM (88).
cytOmegaLOviRuS (cmv)
Cytomegalovirus establishes life-long latency in many organs 
including mucosal tissues. It has long been known that CMV 
infection induces a sustained clonal expansion of specific CD8+ 
T  cells, a phenomenon referred to as memory inflation (89). 
However, only recently has it been explicated that CMV infec-
tion promotes the formation of TRM in various mucosal tissues, 
especially the salivary glands (90–92). Although the CD8+ T cell 
response is vital for the control of CMV infection, the virus-
induced downregulation of MHC I on acinar glandular cells of 
the salivary glands (long-term target tissue of CMV) resulting 
in the reliance on CD4+ T cells for control of lytic replication at 
this site (93). Surprisingly, salivary gland CD8+ TRM were capable 
of controlling viral replication. It appears that murine CMV is 
unable to completely inhibit the expression of MHC I on CD8+ 
TRM of the salivary glands, thereby providing an opportunity 
for these T cells to mediate localized immunity (90). Although 
it remains unclear whether these TRM inhibit viral replication 
through effector cytokines or direct cytotoxicity, it certainly 
appears that salivary gland TRM may inhibit the shedding of CMV, 
hence reducing the chances of transmission. These mucosal TRM 
typically form early after infection. However, mucosal seeding 
continuously occurs through the recruitment and differentiation 
of circulating populations. As such, the immunodominance of 
mucosal TRM against CMV changes with time, favoring the TCR 
repertoire that remains high in circulation (91). TRM have also 
been found in brain tissue after murine CMV infection (94–96). 
In the brain, CMV-specific TRM formation seems to be dependent 
on regulatory T  cell (Treg) activity. Furthermore, Treg cells seem 
to have a suppressive effect on brain TRM’s capacity to produce 
granzyme B, potentially a precautionary measure to prevent 
detrimental neuroinflammation (94). From the studies that have 
dissected the role of TRM in protecting against CMV infection 
and inhibiting reactivation there seems to be a clear role for these 
tissue tropic T cells in limiting CMV replication. A number of 
studies also demonstrate the capacity of CMV to be used as a viral 
vector in novel vaccines that generate TRM-mediated immunity 
(85, 91, 97). Manipulating CMV’s capacity to induce a robust 
CD8+ T cell response within mucosal tissues may be a promising 
avenue for the generation of new vaccines.
LymPHOcytic cHORiOmeNiNgitiS 
viRuS (Lcmv)
Lymphocytic choriomeningitis virus, a rodent-borne disease 
can cause meningoencephalitis in humans (98). While LCMV 
infection models have been used to study TRM in multiple tissues 
(99), the protective role of TRM has only been clearly investigated 
in the brain, thymus, and female reproductive tract. Depletion 
of circulating T cells or NK cells demonstrated that TRM have the 
capacity to protect against infection independently of NK cells, 
TCM, and TEM populations (100, 101). Upon MHC-I-antigen 
stimulation, LCMV brain TRM displayed effector functions and 
mediated virus control through IFN-γ release and perforin-
mediated cytotoxicity (100). Thymic TRM, when stimulated with 
gp33, released both IFN-γ and TNF-α, suggesting that TRM at 
this location may be polyfunctional. It also appears that T cells 
that took residence in the thymus were more likely to respond 
to antigen stimulation when compared to their splenic counter-
parts, further exemplifying the protective nature of these cells 
(101). Since infection of the thymus can significantly reduce 
T  cell generation due to increased thymocyte deletion and 
reduced proliferation, it is vital to have protective mechanisms 
in place that act rapidly to minimize pathogen-induced damage 
in the thymus. From the available evidence, thymic TRM seem 
to be capable of adequately fulfilling this task. LCMV infec-
tion also induces the production of TRM in various peripheral 
tissues, such as the lungs, intestines, and female reproductive 
tract (102–104). While the role of TRM in the lung and intestines 
following LMCV infection is not well established, it was found 
that re-activation of CD8+ TRM in the female reproductive tract 
was able to produce a general anti-viral immune response that is 
almost able to confer sterilizing immunity when challenged with 
an non-cognate virus (105). This TRM induced antiviral state may 
be of great interest in the aim to generate vaccines that create 
heterotypic protection.
vaRiceLLa ZOSteR viRuS
Varicella zoster virus, the cause of chicken pox, is an alpha-
herpes virus that can establish latency within the dorsal root 
ganglia. Reactivation of the virus results in a painful disease 
called shingles. Although vaccines are available against both 
chicken pox and shingles (106), recent evidence suggests 
that TRM may be key players in controlling latent infection, 
a phenomenon that could be exploited to improve current vac-
cines. One study analyzed skin samples from human donors of 
varying ages who were serologically confirmed VZV positive. 
80–90% of T  cells from the sampled tissue expressed CD69, 
suggesting that the majority of T cells in skin were TRM. IL-2 
responses from stimulated VZV-specific T cells demonstrated 
that host age did not influence the numbers of responsive 
cells. However, it was found that skin from older donors dem-
onstrated a lesser capacity to mount a clinical response and 
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decreased CD4+ T cell infiltration when challenged with VZV 
antigen. This correlated with higher proportions of Foxp3+ 
cells. Furthermore, TRM of older skin expressed PD-1 in higher 
amounts (107). Together, this data suggest that VZV-specific 
TRM may be suppressed with age. This may be a reason for the 
high incidence of reactivation of VZV in older individuals. 
Results from a different study that utilized samples of human 
trigeminal ganglia suggests that TRM do not seem to play a role 
in controlling latent infection in the trigeminal ganglia (10). 
Regardless, further investigation into the role of TRM in con-
trolling latent VZV infection may help to develop therapeutics 
or vaccines that prevent shingles.
HumaN PaPiLLOmaviRuS
Human papillomavirus is a sexually transmitted pathogen that 
generally causes an asymptomatic, self-limiting infection. How-
ever, certain subtypes of HPV can cause cancer of the cervix, 
anus, and oropharynx (108). The routine administration of 
HPV preventative vaccines has led to a significant reduction in 
the incidence of infection in many parts of the world. However, 
immunization of individuals with an established HPV infection 
has not shown to protect against the progression of HPV-induced 
lesions into carcinoma. As such, a therapeutic vaccine that is 
administered by post infection may subvert this problem. Current 
HPV vaccines rely on the induction of antibodies to neutralize 
viral particles (109). The potential for generating anti-HPV TRM 
as a strategy for eliminating previously established HPV infection 
is yet to be fully explored. One study evaluated the capacity of 
two adenoviruses (Ad26 and Ad35) that express a fusion of the 
HPV16 oncoproteins E6 and E7 to elicit a protective response 
in the cervicovaginal mucosa. Intra-vaginal administration of 
either vector was able to elicit the generation of CD8+ TRM within 
the cervicovaginal mucosa. Furthermore, systemic priming with 
Ad35 followed by an intra-vaginal booster immunization of Ad26 
induced polyfunctional, E6/E7-specific, cytokine-secreting CD8+ 
T  cells within the cervicovaginal mucosa (110, 111). Although 
it remains to be resolved if protection against established HPV 
infection causally relies on TRM, this and other studies (111) 
provide impetus to further explore the intra-vaginal route of 
administration and the use of viral vectors as strategies for the 
induction of cervicovaginal TRM.
viRaL HePatitiS
Viral hepatitis is an inflammatory disease of the liver that is 
caused by a range of viruses (112). Two studies, both of which 
utilized human donor liver tissue and paired blood samples, 
analyzed the role of TRM in the context of viral hepatitis. One 
study focused on patients with hepatitis B viral infections 
(HBV), while the other study included patients with HBV or 
hepatitis C viral infections. A higher proportion of liver T cells 
from patients who demonstrated partial control of HBV infec-
tion had a TRM phenotype, when compared to healthy controls. 
Given that the overall numbers of T cells in the liver of healthy 
and HBV-infected individuals were similar, this threefold 
increase in TRM numbers appear to be due to an increased 
predisposition of T cells to adopt the TRM phenotype in virally 
infected liver tissue, rather than expansion of pre-existing TRM 
(113). The numbers of T cells co-expressing CD69 and CD103 
increased by fourfold in chronic hepatitis C patients (114). 
Furthermore, the reciprocal relationship between viral loads 
and liver TRM numbers indicates that TRM play a vital role in 
infection control (113). Ex vivo stimulation of TRM showed 
heterogeneous antigen specificity, with a number of HBV 
antigens being able to initiate effector responses. However, viral 
envelope peptides seemed to generate the greatest capacity to 
induce production of IFNγ, TNFα, and IL-2. Analysis of TRM 
from healthy liver tissue revealed a noticeably reduced expres-
sion of granzyme B, when compared to non-resident counter 
parts. This suggests that hepatic TRM have less cytolytic capacity 
than circulating T cells (113, 114). However, liver TRM of patients 
with chronic hepatitis B expressed markedly higher amounts of 
granzyme B when compared to healthy controls (114). Liver TRM 
also showed increased expression of the inhibitory molecule 
PD-1 compared to non-resident T memory cells (113, 114). The 
downregulation of granzyme B and upregulation of PD-1 in 
healthy liver tissue may be a precautionary measure intended 
to prevent immunopathology, given the liver’s role in filtering 
high amounts of antigen draining from the mesenteric circula-
tion. This is of great importance in viral hepatitis infections 
as immunopathology is largely involved in the progression of 
viral hepatitis that leads to cirrhosis and hepatocellular cancer. 
The increased production of granzyme by TRM in CHB patients 
may be part of the pathogenesis of fulminant hepatitis. Further 
exploring the role of TRM in protection against viral hepatitis 
(including hepatitis A, D, and E) and the immunopathology 
implicated in the progression of the disease may aid in the 
development of immunomodulatory therapeutics to prevent 
viral cirrhosis and hepatocellular cancer.
ePSteiN–BaRR viRuS (eBv)
Epstein–Barr virus is one of the most prominent causes of infec-
tious mononucleosis. After exposure to infected saliva, the virus 
infects and replicates in B cells and epithelial cells of the new host. 
Although the clinical disease of glandular fever is usually self-
limiting, EBV remains latent in circulating B cells and episodes 
of reactivation are known to occur. It appears that reactivation 
of EBV occurs in the lymphoid tissue of the oropharynx, where 
the virus switches from a latent form into a lytic cycle. Control 
of infection is mediated by a T  cell response against infected 
B cells (115). EBV-specific CD8+ memory T cells localize to the 
epithelium of the oropharynx (116), where they up-regulate 
CD69 and CD103 in an IL-15- and TGF-β-dependent fashion 
(117). CD103+ EBV-specific T memory cells found in tonsillar 
tissue are more sensitive to antigen stimulation and produce a 
greater effector response when compared to circulating EBV-
specific T cells (116). Furthermore, a substantial CD103+ T cell 
population only seems to appear as viral replication and disease 
tapers (118). Taken together, it appears as though TRM play a 
crucial role in rapidly controlling viral replication of EBV within 
the oropharyngeal tissue upon reactivation to prevent full clinical 
relapse.
10
Muruganandah et al. TRM in Infectious Diseases and Vaccines
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1574
veSicuLaR StOmatitiS  
iNFectiON (vSv)
Vesicular stomatitis infection is a zoonotic disease that can cause 
a mild febrile illness in humans (119). Intranasal infection of mice 
with VSV has shown to produce CD103+ CD8 TRM population 
in the brain (120, 121), as the virus travels along the olfactory 
bulb to the brain where it causes infection. These brain TRM were 
found to be functional in  situ, responding to cognate antigen 
(120, 121). Staining for effector molecules revealed that many of 
these TRM cells were positive for granzyme B, suggesting cytolytic 
abilities. Once removed from the brain parenchyma, these cells 
appear dysfunctional, suggesting they are highly adapted to the 
brain microenvironment. Maintenance of this population of 
TRM appears to be independent of circulating T cells, and BrdU 
incorporation indicates a slow homeostatic rate of proliferation 
to sustain the population (120). Interestingly, brain TRM appear 
to form clusters within specific sites of the brain parenchyma 
that contain CD4+ T  cells, perhaps indicating a role for CD4+ 
T cells in the generation and/or maintenance of brain CD8+ TRM. 
These clusters may have formed around sites of previous VSV 
replication sites, where persisting antigen may be drawing the TRM 
to these locations. Although, viral RNA could not be detected 
at these sites (120), this does not exclude the possibility that 
undetectable levels of antigen may be present at these sites. TRM 
may also form clusters around local dendritic cells that are still 
presenting antigen from a previous infection. This hypothesis is 
supported by the observation that antigen presentation by bone 
marrow-derived-APCs was able to support CD103 expression by 
TRM (120).
OtHeR viRuSeS
Polyomaviruses are opportunistic pathogens that usually remain 
latent following infection. However, in immunocompromised 
individuals, infection can cause multifocal leukoencephalopathy 
(122). TRM are generated in the context of polyomarvirus infec-
tion (123–126), and polyomavirus-specific brain CD8+ TRM in 
mice maintain a high TCR affinity for pathogen epitopes. In fact, 
TRM TCR affinity appears to be higher than the TCR affinity of 
T cells from the spleen. This observation supports a role of TRM in 
mediating rapid control of viral replication during reactivation, 
as high TCR affinity allows for the early detection of low amounts 
of virus (123). In contradiction to this finding, evidence from 
another study suggests that lower TCR stimulation increases 
the generation of brain TRM (125). One way of interpreting 
these seemingly contradicting observations is that brain TRM 
initially differentiate from circulating effector T  cells with low 
TCR stimulation capacity, but after taking residence in the brain, 
undergo functional avidity maturation (127) increasing their 
ability to respond to antigen. A renal transplant clinical study 
suggests that renal BK Polyomavirus-specific TRM were rendered 
incapable of protecting against infection leading to interstitial 
nephritis, likening these TRM to dysfunctional tumor-infiltrating 
lymphocytes (126).
Ebola virus causes a form of hemorrhagic fever characterized 
by intravascular coagulation and maculopapular rash. Although 
the natural reservoirs for the virus are thought to be fruit bats, 
human-to-human transmission can occur when contaminated 
body fluids breach mucosal barriers or skin. Absence of specific 
treatment and epidemic potential of the virus highlights the 
need for a vaccine (128). Aerosol administration of a human 
parainfluenza virus type 3-vectored vaccine expressing an Ebola 
envelope glycoprotein was capable of not only eliciting neutral-
izing antibodies but also a CD103+ T cell response in the lungs of 
macaques. A large proportion of these TRM were polyfunctional, 
demonstrating positivity for two or more activation markers. 
Furthermore, a single dose of this vaccine conferred 100% protec-
tion against infection challenge (129). Since a large proportion 
of transmission in the recent Ebola epidemic was through skin 
contact, vaccination via scarification is worth exploring.
Norovirus is a highly infectious virus, and is a common cause 
of gastroenteritis. Although infection is generally self-limiting, 
chronic forms have been reported in immunocompromised 
patients. A clinical study has implicated CD8+ T cells resembling 
TRM in the immune response against norovirus (130). However, 
a genetically manipulated strain of murine norovirus causing 
chronic infection revealed that despite a robust and functional 
TRM response being generated, clearance of the virus was not 
achieved, likely due to inadequate antigen sensing (131).
tHe ROLe OF tRm iN BacteRiaL 
iNFectiONS
Although there is significantly less literature about TRM in the 
context of bacterial infections, the evidence largely implies that 
TRM have a noteworthy role in protecting against pathogenic bac-
teria. The following section groups bacterial pathogens together 
depending on their location of primary infection.
BacteRiaL iNFectiONS OF tHe LuNgS 
aND aiRwayS
Pertussis, also known as whooping cough, is caused by Bordetella 
pertussis, a Gram-negative coccobacillus. Despite high vaccina-
tion coverage, whooping cough remains a serious public health 
concern. T  cell responses are critical for immunity against 
B. pertussis (132). While the existing whole-cell pertussis (wP) 
vaccine is generally associated with a strong Th1 response, 
immunization with the widely used acellular pertussis (aP) 
vaccine induces a Th2-dominated humoral response (133). 
Immunity to the aP vaccine wanes over time compared to 
wP vaccines (134). This diminished immunity allows for the 
transmission of B. pertussis to susceptible individuals. A recent 
study reported that following B. pertussis infection, IL-17- and 
IFN-γ-secreting CD4+ TRM congregate in the lungs of infected 
mice where they persisted for 120  days, and expanded up to 
sixfold upon reinfection. Egress inhibitor FTY720 did not 
affect the control of bacterial burden during secondary infec-
tion, suggesting that TRM were capable of providing immunity 
irrespective of peripheral T cell recruitment. Bacterial clearance 
in reinfected mice also correlated with CD4+ TRM expansion, 
with a large portion of cells displaying a Th17 phenotype (135). 
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Adoptive transfer of lung CD4+ TRM from infected mice into 
naïve hosts conferred protection against B. pertussis challenge 
(135), suggesting that Th17-like CD4+ TRM seemed to play a 
crucial role in long-term immunity. Interestingly, γδ T  cells 
that express CD69 and CD103, classically known to provide 
innate-like protection during primary infection, also provided 
a significant early-release IL-17 response during secondary 
infection in convalescent mice. However, γδ TRM, especially 
Vγ4+ γδ T cells persisted in the lungs of convalescent mice and 
produced a greater IL-17 response on re-exposure to B. pertussis 
in an antigen-specific manner (136). Therefore, a long-lasting 
B. pertussis vaccine should not only promote the generation of 
B. pertussis-specific CD4+ TRM but also γδ TRM.
Pneumonia is one of the largest infectious causes of morta-
lity in children worldwide (137). The most common cause of 
community-acquired pneumonia is Streptococcus pneumoniae, 
a Gram-positive polysaccharide-encapsulated bacterium (138). 
Modern pneumococcal vaccines are polysaccharide based and 
are thus poorly immunogenic, providing serotype-specific 
immunity that wanes over time. Although CD4+ Th17 responses 
are considered vital in providing protection against pneumococ-
cal infections, the role of TRM is yet to be fully characterized. 
Experimental S. pneumoniae infection was found to promote 
the production of heterotypic CD4+ TRM of both Th17 and Th1 
phenotypes in niches located within pneumonia-affected lobes 
of the lung. It was also observed that immunity was restricted 
to pathogen-experienced tissue, suggesting that TRM reside in 
primary infection sites, rather than providing immunosur-
veillance throughout the entire respiratory mucosa. Despite 
spatial restriction, TRM provided superior protection to the local 
tissue when compared to systemic immune responses elicited 
by antigen-specific CD4+ TCM. Neither adoptive transfer of 
splenic CD4+ T cells from infected mice into naïve recipients, 
nor inhibiting lung translocation of circulating CD4+ T  cells 
with FTY720 in pathogen-experienced mice, had a significant 
effect on protection against pneumococcal infection challenge. 
Therefore, protective immunity against bacterial pneumonia is 
likely due to the aggregation of CD4+ TRM in susceptible tissues 
(139). Interestingly, combining whole virion influenza and 
whole cell pneumococcal vaccine also promoted the generation 
of lung CD4+ TRM. It is likely that these TRM, in combination 
with the accompanying high antibody titers elicited by the 
combined vaccine, played a role in providing protection against 
pneumococcal-influenza co-infection (140). Overall CD4+ TRM 
may play a role in the generation of naturally acquired immunity 
against pneumococcal infections, and should be considered in 
the development of heterotypic pneumococcal vaccines.
Mycobacterium tuberculosis (Mtb), an acid-fast staining intra-
cellular bacterium, is the causative agent of tuberculosis (TB). 
The deadly infection can present as pulmonary, as well as extra 
pulmonary disease (141). Currently, Bacillus Calmette–Guérin 
(BCG) is the only licensed vaccine against TB, and prevents dis-
semination in children. However, BCG does not provide strong 
enough immunity against pulmonary TB in adults, therefore, 
allowing transmission (142). Immune control of Mtb infection 
largely relies on the production of IFNγ by CD4+ T cells, which 
enhances macrophage killing of persisting intracellular Mtb and 
leads to the formation of granulomas around sites of bacterial 
replication (141). A clinical study revealed that individuals previ-
ously exposed to tuberculosis were likely to have a population of 
lung-resident Th1 effector memory cells that released IFN-γ in 
response to Mtb antigen re-exposure (143). However, the delay 
in activation and recruitment of TB-specific T cells to the lungs 
during primary infection allowed for Mtb to proliferate, resulting 
in a high bacterial burden. The importance of airway-residing 
memory T cells (then called airway luminal cells) in mediating 
protection against TB has been described well before the dawn 
of TRM (144–146). However, these cells most likely represent the 
same cell type. Lung TRM induced by mucosal vaccination have 
shown to be effective in limiting the early control of bacterial 
replication (147). Despite the defined role of CD4+ T  cells in 
controlling TB, recent evidence from vaccine studies suggest 
that CD8+ lung TRM also play an important role in protection 
against Mtb (148, 149). Only mucosal administration of BCG 
led to the generation of airway TRM that produce higher levels 
of pro-inflammatory cytokines, including IFN-γ than CD8+ TEM. 
Furthermore, adoptive transfer of sorted airway CD8+ TRM from 
BCG-vaccinated mice demonstrated enhanced protection against 
Mtb challenge in recipient mice. Transfer of CD8+ TRM decreased 
the numbers of alveolar macrophages, while increasing the num-
ber of CD4+ T cells and B cells in the infected lung tissues (148). 
It was hypothesized that CD8+ TRM kill Mtb-infected alveolar 
macrophages, thereby depleting intracellular reservoirs of the 
bacteria and limiting the entry into the lung parenchyma (148). 
Likewise, the viral-vectored vaccines SeV85AB and AdAg85A, 
administered via the intranasal route have also shown to elicit 
an immune response that favors the production of CD8+ rather 
than CD4+ TRM (149, 150). In a rhesus monkey model, a cytomeg-
alovirus vector delivering a range of Mtb antigens (RhCMV/TB) 
provided significant protection against tuberculosis, presumably 
through it its ability to generate and maintain pathogen-specific 
CD4+ and CD8+ circulating and more importantly resident 
memory T  cells that selectively express VLA-1 (151). Finally, 
aerosol vaccination with an attenuated Mtb strain lacking sigH 
not only led to an enormous influx of T cells expressing CD69 
into the lung airways (likely to include TRM), but also to a signifi-
cant long-term protection against virulent Mtb challenge (152). 
Collectively, these studies indicate that rationally designed TB 
vaccines should generate immune responses that prevent the 
establishment of infection and/or provide sterilizing immunity 
by inducing both lung CD4+ TRM and CD8+ TRM in the lungs.
BacteRiaL iNFectiONS OF tHe 
uROgeNitaL tRact
A number of bacteria cause disease of the reproductive tract and 
urinary system. One such example is Ct, an obligate intracel-
lular bacterium that causes infections of the genitals and eyes. 
It is the leading cause of infectious blindness worldwide, and 
can cause infertility when sexually transmitted (153). According 
to clinical evidence, it appears that spontaneous clearance of 
clinical infection correlates with at least partial protection against 
C. trachomatis through the production of INF-γ-secreting cells 
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such as CD4+ Th1 cells. However, IFN-γ responses alone do not 
seem to provide complete protection. It has also been docu-
mented that B cell-antibody responses are involved in immunity, 
especially against secondary infection (154–156). Importantly, 
intraepithelial CD8+ lymphocytes and MLCs composed of B cells 
and CD4+ T cells border the vaginal and uterine tract, respectively 
in pathogen-experienced tissue. These immunocyte structures 
hinder C. trachomatis from replicating and establishing a clinical 
infection (157). Optimal protection against Chlamydia requires 
both the recruitment of TCM and the presence of TRM within the 
urogenital tract (158, 159). It is likely that protective immunity 
occurs in response to chronic or repeated infection, which leads 
to the seeding of TRM throughout the epithelial surface (160). 
A vaccine composed of Chlamydia major outer membrane 
protein and ISOCMATRIX adjuvant was able to provide enough 
protection to prevent the sexual transmission of C. trachomatis, 
however, was not capable of providing complete immunity. This 
may be attributed to the inability of the vaccine to generate a large 
enough TRM population, underscoring the essential role of TRM in 
Chlamydia infection (159). In a separate study, mice were either 
inoculated with infectious C. trachomatis or UV-inactivated 
C. trachomatis (UV-Ct). Mice infected with the infectious form 
demonstrated capacity to control future infections better than 
naïve controls, which may be attributable to the production of 
both Chlamydia-specific TCM and TRM populations. However, the 
group of mice inoculated with UV-Ct suffered higher bacterial 
burdens when compared to naïve controls. This data in conjunc-
tion with the generation of de novo Ct-specific Treg suggest that 
a tolerogenic immune response occurred in these mice. On the 
contrary, intra-uterine administration of UV-Ct conjugated with 
charge-switching synthetic adjuvant peptides (UV-Ct-cSAP) 
conferred a superior protection to Ct in both conventional and 
humanized mice. The rapid clearance of Ct in UV-Ct-cSAP-
vaccinated mice has been attributed to the immediate release of 
IFN-γ by mucosal TRM (158). Taken together, the ideal vaccine 
against Chlamydia should promote the generation of local MLC, 
TCM, and TRM in the epithelium, even though partial protection 
appears to be sufficient to prevent disease transmission.
BacteRiaL iNFectiONS OF tHe 
gaStROiNteStiNaL tRact
Gastrointestinal infections are generally acquired through inges-
tion of contaminated food or water. These bacteria may remain 
in the gut, or may disseminate to other parts of the body causing 
systemic disease (161). Targeted induction of TRM along the gas-
trointestinal epithelium could enhance protection against these 
pathogens. Listeria monocytogenes, a food-borne Gram-positive 
coccobacillus, is of particular concern in immunocompromised 
and pregnant individuals, and can cause meningitis and stillbirth 
(162). Its capacity to replicate within host cells facilitates immune 
evasion. Thus, protection against L. monocytogenes is largely 
dependent on cell-mediated immunity (163). First observed 
in 1981 as a distinct population of long-lived T memory cells 
“positioned” in tissue following listeriosis (164), a more recent 
study highlighted the role of intestinal CD8+ TRM in mediating 
immunity against L. monocytogenes following oral infection. In 
fact, blockage of integrin α4β7 prevented the formation of these 
intestinal TGF-β-dependent TRM resulting in diminished protec-
tion upon re-challenge (165). Revealed by multi-photon dynamic 
microscopy, a population of Vγ4+ γδ TRM was found within 
the mesenteric lymph nodes in response to L. monocytogenes 
infection, which remained largely stationary under homeostatic 
conditions. However, upon re-challenge, activation of these cells 
resulted in organized clusters around bacterial replication foci 
where they released IL-17 and subsequently, the recruitment of 
neutrophils to facilitate bacterial elimination. Similarly to γδ TRM 
function seen in B. pertussis infection (136), neutralization of 
IL-17 hindered bacterial clearance, highlighting the importance 
of early IL-17 release by γδ TRM (166).
Yersinia pseudotuberculosis (Yptb), a food-borne pathogen 
causing of Far East scarlet-like fever, is a Gram-negative bacte-
rium responsible for gastroenteritis, mesenteric lymphadenitis, 
and can clinically mimic acute appendicitis (167). A Yptb oral 
infection mouse model showed a robust CD8+ T  cell response 
in the intestines including a population of Yptb-specific CD103+ 
CD8+ TRM uniformly distributed throughout the intestine, while 
CD103− TRM formed around sites of primary infection where they 
carried out effector functions (168). Although found in antigen-
rich areas, their development is independent of local antigen 
stimulation (168). The development of TRM populations in the 
intestine seems to rely on inflammatory signals from the site of 
infection rather than antigens (169). Production of IFN-β and 
IL-12 from intestinal macrophages effectively suppresses TGF-β-
mediated CD103 expression thereby leading to the development 
of CD69+ CD103- TRM population in mice during Yptb infection. 
This data suggest a central role for inflammatory monocytes in 
the differentiation and maintenance of different CD8+ TRM popu-
lations to achieve optimal protection against intestinal infections. 
Additionally, this study raises the question as to whether CD103 
is necessary for residence within the intestinal tissue, or whether 
it negatively regulates TRM capacity to migrate within their resi-
dential tissues.
Salmonella spp. is a group of Gram-negative bacilli that is a 
common cause of gastrointestinal infections responsible for 
“food poisoning.” Transmitted orally, this heterogeneous group 
of bacteria contains typhoid or enteric-fever causing serovars 
that can be potentially fatal to humans (170). Current vaccines 
against Salmonella are poorly immunogenic and risk disease in 
immunocompromised individuals (171). An effective vaccine 
that prevents gastrointestinal infection is much needed to prevent 
outbreaks of salmonellosis. Subcutaneous co-administration of 
Salmonella SseB and flagellin has shown to provide protection 
against systemic disease in mice. However, parabiosis studies 
suggest that this protection can be transferred via the circulation, 
diminishing the role of TRM in the observed immunity (172). 
Nevertheless, it may be beneficial to assess the capacity of this 
vaccine and others to protect against gastrointestinal infection 
by oral administration. However, the barriers of oral tolerance 
and destruction of vaccine components by digestive enzymes and 
chemicals must be overcome in order to develop oral vaccines.
In summary, TRM responses in bacterial infections appear to 
be more diverse compared to viral infections, an observation that 
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may be attributed to the varying locations of bacterial replication 
(intracellular versus extracellular), the more complex lifestyles 
and the presence or more sophisticated immune evasion mecha-
nisms. Future studies should assess the role of TRM in the natural 
immune response to other bacterial infections.
tHe ROLe OF tRm iN PaRaSitic 
(PROtOZOa aND HeLmiNtHS) 
iNFectiONS
Protozoa are unicellular organisms that are of great importance 
to human health. Most prevalent in tropical regions of the 
world, protozoan infections are difficult to treat due to their 
complex life cycles and their ability to evade host immune 
responses through antigenic variation, residence within various 
intracellular compartments, and their capacity to assume pro-
tective forms such as cysts (173, 174). At this juncture, our col-
lective understanding of TRM responses to protozoan infections 
remains relatively deficient. However, studies have shown that 
TRM play a significant role in protecting against a few protozoan 
species.
Malaria, the most prevalent protozoan infection of humans, 
is caused by five species of Plasmodium. Transmitted by the bite 
of an infected female Anopheles mosquito, Plasmodium parasites 
enter the circulation and take residence inside erythrocytes 
during part of their complex life cycle. Natural immunity to 
Plasmodium infection involves a mixture of humoral, CD4+, 
and CD8+ T  cell responses (175). However, liver TRM have 
emerged as a promising target for protecting against malaria 
(176). Unlike TRM of the epithelium, such as the lungs, intes-
tines, and skin, liver-TRM appear to reside in sinusoids (the 
blood vessels of the liver), rather than the parenchymal tissue 
(177–179). The heavily fenestrated architecture of these blood 
vessels and the distinct slow flow rate of blood allows for TRM 
to traverse through the organ without being dispatched into 
circulation. Furthermore, liver sinusoids provide a prime niche 
for close interaction of TRM and antigen presenting cells, such 
as Kupffer cells and dendritic cells. This allows for the rapid 
detection of antigen. Each hepatocyte is also in close associa-
tion with a sinusoid, thereby providing easy access to liver TRM 
for assessment of surface antigen presentation (177). Intravital 
imaging revealed that these TRM traversed around 10  µm per 
minute and, as reported in HSV-1 infection of skin, TRM assume 
an amoeboid form, extending dendrites to survey the liver 
for antigens (2). Rather than relying on CD103-αE integrin 
interactions for maintaining tissue residence, liver TRM appear 
to utilize the adhesion molecule LFA-1 (3). A rhesus monkey 
P. knowlesi infection model that assessed sporozoite immuni-
zation demonstrated capacity for generating liver TRM. These 
TRM appear to be protective as their depletion resulted in the 
loss of immunity (1). Experiments with radiation-attenuated 
sporozoites also support the notion that inducing high num-
bers of liver TRM can afford protection against malaria. In this 
study, a “prime-and-trap” strategy was used in which primed 
T cells from the spleen were drawn to the liver using a recom-
binant adeno-associated virus that infected hepatocytes and 
subsequently caused them to express Plasmodium antigen. 
The immunity generated by this strategy was attributed to the 
increased numbers of CD8+ liver TRM (2). The emergence of liver 
TRM as a potential target for pre-erythrocytic malaria vaccines 
warrants further research.
Leishmaniasis is a heterogeneous vector-borne disease that 
is caused by an intracellular protozoa parasite. There are over 
20 known leishmania species, all of which are transmitted by 
bites from infected female Phlebotomine sandflies. Clinical dis-
ease presents in three main forms: cutaneous, mucocutanous, 
and visceral. Subjugation of Leishmania parasites relies on 
the establishment of IFN-γ-producing CD4+ Th1 cells (180). 
While it is widely known that clearance of primary infection 
can lead to protective immunity, the effector response that 
leads to protection remains unclear. It has, however, become 
apparent that TRM play a crucial role in providing such pro-
tection (181–183). L. major infection models illustrated that 
following infection, long-lived TRM are rapidly fabricated and 
seeded universally throughout the skin, as they can be detected 
in tissue far away from the primary site of infection (181). 
It was previously believed that these TRM provided immunity 
by rapidly recruiting circulating effector T  cells. However, 
more recent studies suggest that the recruitment of circulat-
ing T  cells may not be as important as previously thought, 
as FTY720 and αCXCR3-treated mice re-challenged with 
L. major showed minimal difference in early parasite control 
(182, 183). Furthermore, parabiosis studies demonstrated that 
Leishmania-specific circulating T cells alone provide little or 
no protection during early infection. Data exemplifies that 
CD4+ TRM are rather likely to provide immunity by eliciting 
a delayed-type hypersensitivity response. Early immunity is 
attributable to the capacity of TRM to rapidly recruit reactive 
oxygen species/nitric oxide producing inflammatory mono-
cytes to control parasite burden (182). Liver TRM have also 
been implicated in the immune response against Leishmania. 
The recombinant proteins LirCyp1 and LirSOD of L. infantum 
appear to be good candidates for promoting the expansion 
of liver memory T  cells (184). No current vaccine exists for 
this potentially fatal disease. Together, these data suggest that 
Leishmaniasis vaccines should be tailored to generate TRM to 
provide heterotypic protection against the many species that 
cause disease.
Toxoplasma gondii, the causative agent of toxoplasmosis, is 
an intracellular protozoan that is generally acquired through 
contaminated food. In humans, T. gondii can form persistent 
cysts in multiple tissues (185). In both acute and chronic 
infection, cell-mediated immunity and effector cytokines play 
vital roles in limiting the progression of disease (186). Mice 
deficient in TNF-α suffer from increased pathology, and IFN-γ 
production in the brain stimulates microglia and astrocytes to 
inhibit protozoan proliferation. In a chronic infection model of 
T. gondii, CD103+ CD8+ TRM established in the brain produced 
a more robust IFN-γ and TNF-α response when compared to 
CD103− T cell subsets (187). It appears that brain TRM provide 
superior protection against T. gondii infection of the central 
nervous system when compared to CD8+ TEM and TCM. During 
T. gondii and Y. pseudotuberculosis infection TRM also seem to 
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accumulate in white adipose tissue in what appears to be a depot 
of protective memory cells (188).
Helminthic infections are highly prevalent around the world. 
Although most infections are not fatal, they account for a large 
proportion of disease burden, causing secondary conditions, 
such as anemia and malnutrition. Immunity against helminthic 
infection is largely mediated by the Th2 effector arm of the adap-
tive immune system (189). The role of TRM in protecting against 
helminthic infections, however, has only been explored recently in 
two species: Heligmosomoides polygyrus and Nippostrongylus 
brasiliensis (190, 191). While neither of these species are human 
pathogens, they provide analogous models to gastrointestinal 
helminthic infections and Necator americanus infection in 
humans, respectively (192, 193). Adoptive transfer of perito-
neal-cavity CD4+ TRM from convalescent mice into naïve mice 
prior to H. polygrus infection challenge, has demonstrated that 
peritoneal-cavity derived CD4+ TRM are capable of hindering 
the reproductive capacity of female worms without reducing 
worm burden (190). This phenomenon provides new insight 
into what appears to be a unique interaction between TRM and 
pathogen. A different study that used a N. brasiliensis model 
demonstrated that even a small number of lung-interstitial TRM 
were capable of providing protective immunity. This was con-
firmed as cognate mice treated with FTY720 and lymphotoxin 
beta-receptor fusion protein (which causes lymphopenia) were 
able to clear secondary infection, suggesting that circulating 
T  cells are not necessary to mount a protective secondary 
response (191). In spite of the lack of knowledge surrounding 
the interaction between TRM and helminths, there is a clear role 
for this subset of T cells in worm infections that needs to be 
explored further.
tHe ROLe OF tRm iN FuNgaL 
iNFectiONS
Typically, fungal infections are less frequent compared to viral 
and bacterial diseases. However, due to the increasing use of 
immunomodulatory drugs for cancer and organ transplant 
patients, the increasing incidence of mycosis is of clinical 
importance (194). TRM responses are least studied in the context 
of fungal infections. In fact, only one fungus appears to have been 
used in TRM studies.
Candida albicans is a dimorphic yeast and opportunistic 
pathogen. Although it forms part of the normal commensal 
biome of humans, it can cause infections known as candidiasis 
especially in immunocompromised individuals (195). Skin and 
tongue-resident CD4+ IL-17-producing TRM can provide effective 
protection against C. albicans (196, 197). Murine skin and oral 
infection models demonstrated that during early infection, γδ 
T cells release IL-17 in response to C. albicans invasion (196, 197). 
In skin, by day 7 post-infection, the vast majority of IL-17-
producing cells are of the Th17 phenotype. Eventually, the T cells 
at the site of initial infection upregulate CD103 and CD69 sug-
gesting they assume the CD4+ TRM phenotype between 30 and 
90 days post infection. During this time, the cells first become 
less motile, eventually “sessile” and localize to the papillary 
dermis. However, upon reinfection, these TRM were capable of 
rapidly clearing infection and appear to be superior at doing 
so than circulating TEM. It was also reported that C. albicans-
specific Th17  cells were found in high numbers in normal 
human skin (196), and that low doses of C. albicans antigen 
exposure stimulates the production of regulatory skin TRM that 
substantially suppress the activity of skin TEM (198). This may be 
attributed to the widespread presence of C. albicans in human 
tissue. Resident memory Treg cells may play a protective role in 
preventing a hyper-inflammatory response to benign C. albicans 
antigen exposure. Although the development of a vaccine against 
C. albicans is not of vital importance, these studies provide an 
initial insight into understanding TRM responses to fungal infec-
tions. Other fungal infections that would be of interest include 
tinea, cryptococcosis, and aspergillosis.
DiScuSSiON
The discovery of TRM has enhanced the possibility to develop 
new and improved vaccines. From the available literature, it 
appears that the most important factor for generating TRM is to 
match the route of vaccination to the route of pathogen entry. 
In general, these are the mucosal and epithelial barriers that pro-
vide the first line of defense against pathogens: the respiratory, 
gastrointestinal, urogenital mucosa, and integumentary epithe-
lium (Figure 3). Thus, the long-standing method of adminis-
tering vaccines parenterally may be less effective at conferring 
optimal protection when compared to the novel mucosal and 
epithelial vaccine strategies highlighted throughout this review. 
The “prime and pull” method in which a parenteral vaccine is 
administered (prime) and an inflammatory agent is applied at 
a later time point to the desired peripheral tissue (pull) has also 
proven itself to be an effective vaccine strategy for generating 
TRM. The combination of mucosal vaccination and “pull” strate-
gies may be an avenue worth exploring in future experiments. 
Another promising vaccine strategy is the use of viral-vectored 
vaccines. Regardless, it is also imperative to keep in mind the 
balance that these tissues must constantly strike in inducing a 
tolerogenic versus effector immune response to antigens, given 
their dual function in both their physiological roles (respira-
tion, digestion, reproduction, etc.) and in serving as barriers 
against infection. Additionally, it will be important to consider 
the local cytokine milieu that influences TRM generation (199). 
Generating memory T cells in peripheral tissues with cytolytic 
effector functions and the capacity to recruit inflammatory 
cells may pose the risk of inducing a hyper-inflammatory state 
leading to immunopathology. However, the natural persistence 
of TRM in most peripheral tissues for extended periods of time 
under homeostatic conditions implies that mechanisms are in 
place to regulate TRM responses. Developing a greater under-
standing of these mechanisms is vital in creating safe TRM-based 
vaccines.
A very appealing aspect of TRM-based vaccines is that it may 
be possible to generate heterotypic protection, as shown by stud-
ies using influenza infection models. This is vital for protecting 
against a range of rapidly mutating pathogens, such as HIV, as 
well as infectious diseases such as leishmaniasis that are caused 
FiguRe 3 | Visual summary of key TRM effector responses and vaccine strategies at epithelial surfaces. (a) Represents the female reproductive tract. Topical 
application of both specific chemokines and general inflammatory agents such as nonoxynol-9 can be used to “pull” systemically primed TEM into the mucosal 
tissue. CD103+ TRM reside closer toward the apical surface of the mucosa. Both CD4+ and CD8+ TRM play a role in controlling viral infections. Memory lymphocyte 
clusters have been shown to be important in controlling infections at this site. CD8+ TRM re-stimulation appears to be dependent on CD301b+ dendritic cells that 
reside in the lamina propria. (B) Represent the integumentary epithelium. Topical application of both specific chemokines and general inflammatory agents such 
as 2,4-dinitroflourobenzene can be used to “pull” systemically primed TEM into the epidermal tissue. Skin scarification as a route of vaccination encourages  
the development of skin TRM. Upon antigen recognition, skin TRM lose their dendricity and become less motile. γδ TRM can mediate early immune responses.  
CD8+ αα+ TRM have been found in the dermal–epidermal junction where they may be able to survey local neural tissue for reactivation of latent viral infections.  
(c) Represents the respiratory epithelium. While different chemokines have shown the ability to “pull” TRM into the respiratory epithelium and airways, the 
presence of antigen appears to be important at this site. TRM-mediated control of Streptococcus pneumoniae is largely dependent on the CD4+ subset.  
Control of viral and Mycobacterium tuberculosis infection requires both CD4+ and CD8+ TRM. γδ TRM, in conjunction with CD4+ TRM have been shown to  
mediate immunity against Bordetella pertussis.
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by heterogeneous pathogens. Furthermore, the promptitude with 
which TRM mediate immune responses is also of great interest 
when generating protection against infections such as tubercu-
losis that are capable of establishing latent infections. In order 
to achieve immediate TRM protection, it appears that there must 
be a minimal density of TRM within peripheral tissues to ensure 
pathogens are identified and eliminated in a timely manner. This 
may pose a challenge in developing TRM-based vaccines as suffi-
cient numbers of TRM need to be generated and maintained evenly 
throughout infection-susceptible tissues. The spatial capacity in 
non-lymphoid tissue to accommodate for TRM may be limited, 
and thus establishing the capacity of different tissues has as well 
as determining the minimum threshold of TRM needed to provide 
protection is much needed.
cONcLuSiON
In summary, the findings of this review largely accentuate the 
importance of TRM in protecting against a range of pathogens. 
Their localization to sites prone to infection appears to give TRM an 
enhanced capacity to mount swifter immune responses when com-
pared to circulating memory T cells. Previous vaccine development 
has been largely centered on the generation of systemic memory 
response, which at times has shown to be ineffective. The capacity 
to form tissue-specific immunity through TRM may shape vaccines 
of the future. Continuing to foster the growing pool of knowledge 
about TRM will help to guide the field of TRM vaccinology and may 
lead to the generation of new and more effective vaccines which 
may help to reduce the incidence of many infectious diseases.
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